industry biopharmaceuticals founded 1990 headquarters san francisco california products exubera movantik 1 revenue 148.92 million as of 2013 update 2 website www.nektar.com nektar therapeutics nektar nasdaq nktr is an american biopharmaceutical company . the company was founded in 1990 and is based in san francisco california . 3 the company develops new drug candidates by applying its proprietary pegylation and advanced polymer conjugate technologies to modify chemical structure of substances . 4 it is a technology supplier to a number of pharmaceutical companies including affymax amgen merck pfizer and ucb pharma etc. 3 the company developed the world s first inhalable non injectable insulin exubera which was awarded as the bronze award by wall street journal for its technological breakthrough . exubera was also recognized as the most innovative diabetes medicine of 2006 in germany . 5 background edit the company is engaged in developing a propriety pipeline of drug candidates for several therapeutic areas including oncology pain anti infectives anti viral and immunology . 3 the company s research and development involve in small molecule and biologic drug candidates . its drug candidate base consists of naloxegol movantik a phase iii oral opioid antagonist etirinotecan pegol a topoisomerase inhibitor under phase iii clinical study as of 2012 nktr 061 nktr 181 nktr 214 etc. 6 in 2013 the company was assignment a patent which was developed by the company and other four co inventors . 7 the products of the company is served as a supplement to improve the pharmacokinetics pharmacodynamics half life bioavailability and other areas of drugs for the patients worldwide . 8 as of march 2014 the company had an market capitalization of 1.7 billion with an enterprise value of 1.67 billion . 2 pipeline edit etirinotecan pegol was in the phase iii beacon trial and is in the i spy2 adaptive clinical trial for breast cancer . 9 references edit nektar therapeutics profile http finance.yahoo.com q pr s nktr profile a b nktr key statistics nektar therapeutics inc stock yahoo finance . finance.yahoo.com . retrieved 2014 03 16 . a b c bdr summary for nektar therapeutics inc. yahoo finance . finance.yahoo.com . retrieved 2014 03 17 . nextar therapeutics inc. brief introduction nasdaq . nasdaq.com . retrieved 2014 03 16 . exubera hailed as innovation in prestigious european and american awards . prnewswire.co.uk . 2006 09 12 . retrieved 2014 03 16 . nktr reuter.com . reuters.com . retrieved 2014 03 16 . nektar therapeutics u.s. patents awarded to inventors in alabama feb. 8 . 4 traders.com . 2014 02 08 . retrieved 2014 03 16 . nextar marketwatch quote summary . marketwatch.com . retrieved 2014 03 16 . novel agents are targeting drivers of tnbc several drug candidates in i spy2 have graduated to later phase studies . 2016 retrieved from https en.wikipedia.org w index.php title nextar therapeutics & oldid 727994004 categories companies established in 1990publicly traded companies of the united stateshidden categories articles containing potentially dated statements from 2013all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 2 july 2016 at 12 36 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view